Asthma exacerbations · adults and children with exercise‐induced bronchoconstriction/asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lung function: FEV1 % drop Postexercise · adults and children with exercise‐induced bronchoconstriction/asthma
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Low
Asthma symptoms · adults and children with exercise‐induced bronchoconstriction/asthma
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Low
Progression to late AMD (neovascular AMD, geographic atrophy or both) · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy, or both) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to neovascular AMD · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to neovascular AMD compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to geographic atrophy · people with AMD
Antioxidant multivitamin and mineral supplement showed no clear difference in progression to geographic atrophy compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Quality of life · people with AMD
1 finding from 1 review
Adverse effects · people with AMD
Antioxidant multivitamin and mineral supplement may leads to lower adverse effects compared with placebo or no treatment (low certainty).
1 finding from 1 review
Resource use and costs · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic VTE compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
It is very uncertain whether vitamin K antagonists changes symptomatic PE compared with placebo or no thromboprophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic DVT compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic VTE compared with active control (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with active control (low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic PE compared with active control (moderate certainty).
1 finding from 1 review